MBMrinalini Balki

Mrinalini Balki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mrinalini Balki has a total of 181 co-authors. Here are the top co-authors by number of shared publications:

  • Jose C. A. Carvalho

    Department of Anesthesia and Pain Management, Mount Sinai Hospital, Sinai Health, Toronto, Canada

    9 shared publications
  • J.C. Carvalho

    Department of Anesthesia and Pain Management, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

    7 shared publications
  • John Kingdom

    Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

    4 shared publications
  • Kristi Downey

    Department of Anesthesia and Pain Management, Mount Sinai Hospital, Sinai Health, Toronto, Canada

    4 shared publications
  • A. Salman

    Department of Anesthesia and Pain Management, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

    3 shared publications
  • Aliya Salman

    University of Toronto

    3 shared publications

Latest Publications

  • Low-frequency hearing loss after unintentional dural puncture with an epidural needle in obstetric patients

    by Subrata Chakravarty, Vedant Wasade, Jose C. A. Carvalho, Kristi Downey, Eugene Yoon, Mrinalini Balki

  • Spontaneous and oxytocin-induced contractility of gravid human myometrium with exposure to intravenous anesthetic agents: an ex vivo laboratory study

    by Natalia C. Portela, Thomas Drew, Jose C. A. Carvalho, Tess E. Engel, Mrinalini Balki

    Purpose The objective of this study was to investigate the ex vivo effects of various intravenous anesthetic drugs on the contractility of gravid human myometrium. We hypothesized that these drugs would cause a concentration-dependent decrease in spontaneous uterine contractility and oxytocin coadministration would modify their contractile response. Methods We conducted an ex vivo laboratory study with individual myometrial strips obtained from patients undergoing elective Cesarean delivery. We subjected the myometrial strips to concentration–response testing in organ bath chambers with intravenous agents—propofol, etomidate, and ketamine, with or without oxytocin—in a pattern of 0.5 log molar increase from 10−7 M to 10−4 M. The control group received oxytocin alone without any study drug. We recorded contractility parameters, and the primary outcome was the motility index (amplitude × frequency). Results The motility index with each study drug decreased with increasing concentrations. The overall motility index (estimated mean difference [95% confidence interval]) with etomidate (−6% [−77 to −13]; n = 29; P = 0.007) and ketamine (−66% [−82 to −35]; n = 29; P < 0.001) was significantly lower than that of the oxytocin control group, while the difference between propofol and oxytocin was not statistically significant (−38% [−70 to 29]; n = 25; P = 0.47). The addition of oxytocin reversed contractility decreases induced by all anesthetic drugs, with no significant differences observed between the study drug + oxytocin and oxytocin control groups. Nevertheless, when compared with a study drug alone, the addition of oxytocin significantly increased the strength of contraction (area under the curve) of etomidate (207% [30 to 624]; n = 27; P = 0.002) and ketamine (234% [95 to 471]; n = 27; P < 0.001) but not of propofol. Conclusions All the studied intravenous anesthetic drugs produced a concentration-dependent decrease in uterine contractility; nevertheless, the addition of oxytocin reversed this effect and increased contractility. Coadministration with oxytocin of etomidate and ketamine, but not propofol, resulted in a significant increase in myometrial contractility.

  • Open Access

    Propranolol and Oxytocin‐Induced Contractility in Gravid Human Myometrium: An Ex Vivo Laboratory Study

    by Mrinalini Balki, Lauren M. Miller, Jayalakshmi Caliaperumal, Stella Wang, Ella Huszti, John C. Kingdom

    Objective: To determine the effect of propranolol on myometrial contractions induced by low dose and high dose oxytocin.Design: Prospective ex vivo laboratory study.Setting: Mount Sinai Hospital, Toronto.Population: Full‐term parturients who underwent elective caesarean deliveries (CD).Methods: Two models were developed in the organ bath chamber using myometrial samples obtained during CDs: (i) Labor induction‐augmentation model with low‐dose oxytocin consisting of 3 groups with the administration of propranolol before and during simulated labor, and a control group. (ii) Postpartum haemorrhage (PPH) model with high‐dose oxytocin consisting of 4 groups with the administration of propranolol during and/or after augmented labor (desensitised with oxytocin), and a control group.Main Outcome Measures: Myometrial contractility was recorded using force transducers.Results: In the labor induction‐augmentation model, propranolol pre‐treatment produced a higher area under the curve (AUC) of myometrial contractility induced by low‐dose oxytocin (relative percentage difference [diff]: 20.4%; 95% CI [1.4%, 43.2%], p = 0.035) compared to control; however, no difference was observed when propranolol was given after the initiation of labor. In the oxytocin‐desensitised PPH model, the AUC of myometrial contractility induced by high‐dose oxytocin was improved with propranolol pre‐treatment (diff 25.4% [0.2%, 56.8%], p = 0.048), co‐treatment (diff 26.7% [3.7%, 54.7%], p = 0.02), and both pre‐ and co‐treatment (diff 28.4% [7.0%, 54.1%], p = 0.007) when compared to the control group.Conclusions: Our ex vivo study suggests that propranolol can augment uterine activity by approximately 20%–25% when administered early during labor induction and augmentation. Clinical studies are warranted to determine the relevance of these findings in vivo.Trial Registration: ClinicalTrials.gov Identifier: NCT03434444; https://clinicaltrials.gov/


  • Maintenance infusion rate of oxytocin after initial 1-IU bolus for elective Cesarean delivery: a dose-finding study

    by Linda Boonstra, Jose C. A. Carvalho, William Turner, Kristi Downey, Xiang Y. Ye, Jackie Thomas, Mrinalini Balki

    Purpose The purpose of our study was to determine the minimum effective dose of oxytocin maintenance infusion required to maintain adequate uterine tone in 90% of patients (ED90) after administration of the initial bolus at elective Cesarean delivery (CD) under spinal anesthesia. Methods We conducted a prospective, double-blind dose-finding study with biased coin up-down design. Immediately after delivery, a 1-IU oxytocin bolus was administered, followed by a maintenance infusion. The obstetrician assessed the uterine tone by palpation as satisfactory or unsatisfactory. In case of unsatisfactory response, the dose for the next patient was increased by 2 IU·hr−1. For satisfactory response, the dose for the next patient was either decreased by 2 IU·hr−1 with a probability of 1/9, or remained unchanged. The primary outcome was a satisfactory uterine tone from five minutes after delivery until discharge from postanesthesia care unit. The secondary outcomes were blood loss, need for additional uterotonics, and side effects. Results We analyzed data for 40 patients. The ED90 of oxytocin maintenance infusion was 4.5 IU·hr−1 (95% confidence interval, 3.3 to 5.5) based on the isotonic regression estimator. The median [interquartile range] blood loss was 861 [553–1,181] mL; 18% received additional uterotonics, and 38% developed hypotension post delivery. Conclusion Based on the results of this dose-finding study, we recommend a maintenance infusion rate of 4.5 IU·hr−1 following an oxytocin bolus of 1 IU for adequate uterine tone in pregnant patients undergoing elective CDs. This infusion rate is four-fold lower than that required without an initial bolus. Study registration ClinicalTrials.gov (NCT04946006); first submitted 25 June 2021.


  • In Response

    by Oscar F. C. van Den Bosch, Rabail Chaudhry, James Wicker, Talha Mubashir, Daniel Limb, Rohit Jogendran, Laveena Munshi, Mrinalini Balki

  • Carbetocin vs. oxytocin at elective caesarean delivery: a reply

    by M. Balki, F. McDonagh, J. C. A. Carvalho


  • Predictors and Hospital Outcomes in Pregnant Patients Undergoing Extracorporeal Membrane Oxygenation: A Nationwide Study

    by Oscar F. C. van Den Bosch, Rabail Chaudhry, James Wicker, Talha Mubashir, Daniel Limb, Rohit Jogendran, Laveena Munshi, Mrinalini Balki

    BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is increasingly used in patients with severe cardiorespiratory collapse. Although prior large database reviews of ECMO use in the peripartum population exist, they do not stratify by ECMO indication nor do they include obstetric conditions such as preeclampsia. Our objective was to characterize the incidence, indication-associated mortality, and factors associated with mortality in pregnant patients who underwent ECMO. METHODS: We examined the United States National Inpatient Sample database to identify hospitalizations for pregnancy from January 1, 2010 to December 31, 2016. We identified pregnant patients who underwent ECMO using International Classification of Diseases ninth and tenth revisions codes. The primary outcome was in-hospital all-cause mortality across pregnant patients who underwent ECMO for any indication. We evaluated the indication for ECMO, incidence, prevalence of risk factors, comorbidities and conditions, and their association with in-hospital mortality. RESULTS: Fifty-nine of 5‚346,517 pregnant patients underwent ECMO during our study period (incidence, 1.1; 95% confidence interval [CI], 0.84–1.4 per 100,000 hospitalizations). Indications for ECMO support included respiratory failure (79.7%), cardiogenic shock (64.4%), or circulatory arrest (25.4%). Most patients (57.6%) had more than 1 indication. The overall in-hospital mortality rate was 30.5%. Mortality was 29.8% in patients with respiratory failure, 39.5% with cardiogenic shock, 46.7% with cardiac arrest, and 42.4% in those with combined diagnoses. Cardiogenic shock was associated with a significantly higher mortality rate and adjusted odds ratio 5.0 (95% CI, 1.25–27.0). Most patients (62.7%) had one or more comorbidities. CONCLUSIONS: The frequency of ECMO use across the pregnant population was low over this time period, with a mortality rate of 1 in 3 patients. Mortality was greatest in patients with cardiogenic shock. Further work is needed to understand how best to improve ECMO outcomes in pregnant patients.